{"id":"https://openalex.org/W3018908320","doi":"https://doi.org/10.1007/s40262-020-00882-2","title":"Pharmacokinetic Drug\u2013Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer","display_name":"Pharmacokinetic Drug\u2013Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer","publication_year":2020,"publication_date":"2020-04-27","ids":{"openalex":"https://openalex.org/W3018908320","doi":"https://doi.org/10.1007/s40262-020-00882-2","mag":"3018908320","pmid":"https://pubmed.ncbi.nlm.nih.gov/32338345"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-020-00882-2","doi":"https://doi.org/10.1007/s40262-020-00882-2","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40262-020-00882-2","pdf_url":null,"source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://ibn.idsi.md/vizualizare_articol/111795","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036620887","display_name":"Ignacio Dur\u00e1n","orcid":"https://orcid.org/0000-0001-8571-7163","observed_orcids":["https://orcid.org/0000-0001-8571-7163"]},"institutions":[{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ignacio Duran","raw_affiliation_strings":["Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Virgen del Roc\u00edo, Seville, Spain","institution_ids":["https://openalex.org/I4210153139"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001994148","display_name":"Joan Carles","orcid":"https://orcid.org/0000-0002-9983-5934","observed_orcids":["https://orcid.org/0000-0002-9983-5934"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Joan Carles","raw_affiliation_strings":["Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004447476","display_name":"Iurie Bulat","orcid":"https://orcid.org/0009-0008-2211-622X","observed_orcids":["https://orcid.org/0009-0008-2211-622X"]},"institutions":[{"id":"https://openalex.org/I4210108897","display_name":"Institutul Oncologic din Republica Moldova","ror":"https://ror.org/01m92rg76","country_code":"MD","type":"healthcare","lineage":["https://openalex.org/I4210108897"]}],"countries":["MD"],"is_corresponding":false,"raw_author_name":"Iurie Bulat","raw_affiliation_strings":["ARENSIA Exploratory Medicine, Institute of Oncology Unit, Chisinau, Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARENSIA Exploratory Medicine, Institute of Oncology Unit, Chisinau, Moldova","institution_ids":["https://openalex.org/I4210108897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009980783","display_name":"Peter Hellemans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Peter Hellemans","raw_affiliation_strings":["Janssen Research & Development, Beerse, Belgium. phellema@its.jnj.com","Janssen Research & Development, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Beerse, Belgium. phellema@its.jnj.com","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Janssen Research & Development, Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085887211","display_name":"Anna Mitselos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Anna Mitselos","raw_affiliation_strings":["Janssen Research & Development, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Peter Ward","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Ward","raw_affiliation_strings":["Janssen Research & Development, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109192593","display_name":"James Juhui Jiao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Jiao","raw_affiliation_strings":["Janssen Research & Development, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034343267","display_name":"Danielle R. Armas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Armas","raw_affiliation_strings":["Celerion, Tempe, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celerion, Tempe, AZ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112820492","display_name":"Caly Chien","orcid":"https://orcid.org/0009-0002-7054-9536","observed_orcids":["https://orcid.org/0009-0002-7054-9536"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caly Chien","raw_affiliation_strings":["Janssen Research & Development, Spring House, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Spring House, PA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5009980783"],"corresponding_institution_ids":["https://openalex.org/I137982388"],"apc_list":{"value":3860,"currency":"USD","value_usd":3860},"apc_paid":null,"fwci":4.0054,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.95148305,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"59","issue":"9","first_page":"1135","last_page":"1148"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.03779999911785126,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.013500000350177288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apalutamide","display_name":"apalutamide","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8889999985694885},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9179999828338623},{"id":"https://openalex.org/keywords/cyp2c8","display_name":"CYP2C8","score":0.8360000252723694},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.9909999966621399},{"id":"https://openalex.org/keywords/cyp2c19","display_name":"CYP2C19","score":0.8220000267028809},{"id":"https://openalex.org/keywords/cyp2c9","display_name":"CYP2C9","score":0.972000002861023},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.9800000190734863},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.8539999723434448},{"id":"https://openalex.org/keywords/oatp1b1","display_name":"OATP1B1","score":0.9940000176429749},{"id":"https://openalex.org/keywords/itraconazole","display_name":"itraconazole","score":0.7039999961853027},{"id":"https://openalex.org/keywords/gemfibrozil","display_name":"gemfibrozil","score":1.0},{"id":"https://openalex.org/keywords/midazolam","display_name":"midazolam","score":0.8679999709129333},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":0.875},{"id":"https://openalex.org/keywords/omeprazole","display_name":"omeprazole","score":0.9409999847412109},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9259999990463257},{"id":"https://openalex.org/keywords/fexofenadine","display_name":"fexofenadine","score":0.9879999756813049},{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.5419999957084656},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.546999990940094},{"id":"https://openalex.org/keywords/enzyme-inhibitors","display_name":"enzyme inhibitors","score":0.39899998903274536},{"id":"https://openalex.org/keywords/transporter-substrates","display_name":"transporter substrates","score":0.6230000257492065}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7491216063499451},{"id":"https://openalex.org/C115368759","wikidata":"https://www.wikidata.org/wiki/Q14916190","display_name":"CYP2C8","level":5,"score":0.607452392578125},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5921309590339661},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.5335835218429565},{"id":"https://openalex.org/C2777498785","wikidata":"https://www.wikidata.org/wiki/Q422210","display_name":"Omeprazole","level":2,"score":0.5097352862358093},{"id":"https://openalex.org/C140840227","wikidata":"https://www.wikidata.org/wiki/Q3737532","display_name":"CYP2C19","level":4,"score":0.5024681091308594},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.5008647441864014},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.4683270752429962},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45877254009246826},{"id":"https://openalex.org/C3946865","wikidata":"https://www.wikidata.org/wiki/Q5014962","display_name":"CYP2C9","level":4,"score":0.4370485544204712},{"id":"https://openalex.org/C2776711289","wikidata":"https://www.wikidata.org/wiki/Q415122","display_name":"Fexofenadine","level":2,"score":0.4280727505683899},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.41162675619125366},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.38210317492485046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3329033851623535},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.2604883015155792},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013867","descriptor_name":"Thiohydantoins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D064129","descriptor_name":"Prostatic Neoplasms, Castration-Resistant","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40262-020-00882-2","doi":"https://doi.org/10.1007/s40262-020-00882-2","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40262-020-00882-2","pdf_url":null,"source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmid:32338345","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32338345","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Journal Article"},{"id":"pmh:oai:ibn.idsi.md:111795","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/111795","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacokinetics 1135-1148","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:ibn.idsi.md:111795","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/111795","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacokinetics 1135-1148","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337415","display_name":"Janssen Research and Development","ror":"https://ror.org/03qd7mz70"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1914180058","https://openalex.org/W1982021449","https://openalex.org/W1991626196","https://openalex.org/W2030021013","https://openalex.org/W2037131718","https://openalex.org/W2037356751","https://openalex.org/W2045221999","https://openalex.org/W2049218137","https://openalex.org/W2049869379","https://openalex.org/W2054911076","https://openalex.org/W2063464585","https://openalex.org/W2065619484","https://openalex.org/W2068634821","https://openalex.org/W2075326549","https://openalex.org/W2109989116","https://openalex.org/W2134565544","https://openalex.org/W2143891871","https://openalex.org/W2168018544","https://openalex.org/W2171167058","https://openalex.org/W2320771407","https://openalex.org/W2512647917","https://openalex.org/W2523790029","https://openalex.org/W2599138642","https://openalex.org/W2604711452","https://openalex.org/W2792086148","https://openalex.org/W2881471750","https://openalex.org/W2917593000","https://openalex.org/W2947014957","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W3018168093","https://openalex.org/W1999742630","https://openalex.org/W2920834535","https://openalex.org/W7131638489","https://openalex.org/W7101093746","https://openalex.org/W4293230230","https://openalex.org/W2977338802","https://openalex.org/W4411013475","https://openalex.org/W2900890182","https://openalex.org/W4381550549"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Two":[3],"phase":[4],"I":[5],"studies":[6],"assessed":[7],"the":[8,103],"drug-drug":[9],"interaction":[10],"potential":[11],"of":[12,36,91,158,172],"apalutamide":[13,28,92,109,146,159],"as":[14],"a":[15,143],"substrate":[16],"and":[17,62,65,72,86,137,152],"perpetrator.":[18],"METHODS:":[19],"Study":[20],"A":[21],"randomized":[22],"45":[23],"healthy":[24],"men":[25],"to":[26,95,107,126],"single-dose":[27,108],"240":[29,93],"mg":[30,94],"alone":[31],"or":[32,41,166],"with":[33,49,112,118,160],"strong":[34],"inhibitors":[35],"cytochrome":[37],"P450":[38],"(CYP)3A4":[39],"(itraconazole)":[40],"CYP2C8":[42,63],"(gemfibrozil).":[43],"In":[44],"study":[45],"B,":[46],"23":[47],"patients":[48],"castration-resistant":[50],"prostate":[51],"cancer":[52,74],"received":[53],"probes":[54],"for":[55,68,174],"CYP3A4":[56],"(midazolam),":[57],"CYP2C9":[58],"(warfarin),":[59],"CYP2C19":[60],"(omeprazole),":[61],"(pioglitazone),":[64],"transporter":[66],"substrates":[67,168],"P-glycoprotein":[69],"(P-gp)":[70],"(fexofenadine)":[71],"breast":[73],"resistance":[75],"protein":[76],"(BCRP)/organic":[77],"anion":[78],"transporting":[79],"polypeptide":[80],"(OATP)":[81],"1B1":[82],"(rosuvastatin)":[83],"at":[84],"baseline":[85],"after":[87],"repeat":[88],"once-daily":[89],"administration":[90],"steady":[96],"state.":[97],"RESULTS:":[98],"Systemic":[99],"exposure":[100,125],"(area":[101],"under":[102],"plasma":[104],"concentration-time":[105],"curve)":[106],"increased":[110],"68%":[111],"gemfibrozil":[113],"but":[114],"was":[115],"relatively":[116],"unchanged":[117],"itraconazole":[119],"(study":[120,140],"A).":[121],"Apalutamide":[122],"reduced":[123],"systemic":[124],"midazolam":[127],"\u219392%,":[128],"omeprazole":[129],"\u219385%,":[130],"S-warfarin":[131],"\u219346%,":[132],"fexofenadine":[133],"\u219330%,":[134],"rosuvastatin":[135],"\u219341%,":[136],"pioglitazone":[138],"\u219318%":[139],"B).":[141],"After":[142],"single":[144],"dose,":[145],"is":[147],"predominantly":[148],"metabolized":[149],"by":[150,154],"CYP2C8,":[151],"less":[153],"CYP3A4.":[155],"CONCLUSIONS:":[156],"Co-administration":[157],"CYP3A4,":[161],"CYP2C19,":[162],"CYP2C9,":[163],"P-gp,":[164],"BCRP":[165],"OATP1B1":[167],"may":[169],"cause":[170],"loss":[171],"activity":[173],"these":[175],"medications.":[176],"Therefore,":[177],"appropriate":[178],"mitigation":[179],"strategies":[180],"are":[181],"recommended.":[182]},"counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2020-05-01T00:00:00"}